Citius Oncology, Inc. Financials
Financial Health Signals
Citius Oncology, Inc. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Citius Oncology, Inc. generates $0.22 in operating cash flow (-$5.5M OCF vs -$24.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Citius Oncology, Inc. earns $-107.9 in operating income for every $1 of interest expense (-$23.5M vs $218K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Citius Oncology, Inc. (CTOR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Citius Oncology, Inc. reported -$24.8M in net income in fiscal year 2025. This represents a decrease of 17.1% from the prior year.
Citius Oncology, Inc. earned $-0.34 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 9.7% from the prior year.
Citius Oncology, Inc. held $3.9M in cash against $0 in long-term debt as of fiscal year 2025.
Citius Oncology, Inc. had 84M shares outstanding in fiscal year 2025. This represents an increase of 16.7% from the prior year.
Citius Oncology, Inc. invested $6.4M in research and development in fiscal year 2025. This represents an increase of 30.3% from the prior year.
CTOR Income Statement
| Metric | Q1'26 | Q1'25 | Q3'25 | Q1'24 | Q3'24 | Q3'23 | Q2'23 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.9M0.0% | $3.9M | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | $789K0.0% | $789K | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $3.2M0.0% | $3.2M | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $1.0M0.0% | $1.0M+8.5% | $938K-25.8% | $1.3M+11.8% | $1.1M-1.5% | $1.1M | N/A | N/A |
| SG&A Expenses | $2.9M0.0% | $2.9M+52.0% | $1.9M-43.4% | $3.3M+115.7% | $1.5M+1.5% | $1.5M+660.7% | $200K | N/A |
| Operating Income | $5.3M+200.0% | -$5.3M-6.2% | -$4.9M+22.7% | -$6.4M-38.2% | -$4.6M-998.3% | -$421K-111.2% | -$200K | N/A |
| Interest Expense | $46K0.0% | $46K-71.5% | $161K | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $264K0.0% | $264K0.0% | $264K0.0% | $264K+83.5% | $144K0.0% | $144K | N/A | N/A |
| Net Income | $5.5M+200.0% | -$5.5M-3.1% | -$5.4M+19.4% | -$6.7M-39.5% | -$4.8M-1.0% | -$4.7M-867.1% | $616K | N/A |
| EPS (Diluted) | $0.06+200.0% | $-0.06+25.0% | $-0.08+11.1% | $-0.09-28.6% | $-0.07 | $-0.07-200.0% | $0.07 | N/A |
CTOR Balance Sheet
| Metric | Q1'26 | Q1'25 | Q3'25 | Q1'24 | Q3'24 | Q3'23 | Q2'23 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $110.0M0.0% | $110.0M+19.9% | $91.7M+1.4% | $90.5M+7.2% | $84.4M+16.2% | $72.6M+4.0% | $69.9M+2.4% | $68.2M |
| Current Assets | $37.1M0.0% | $37.1M+102.9% | $18.3M+7.2% | $17.1M+55.7% | $11.0M+18746.9% | $58K-87.4% | $462K+22.4% | $377K |
| Cash & Equivalents | $7.3M0.0% | $7.3M+6513695.5% | $1120.0% | $1120.0% | $112-99.7% | $33K-91.2% | $370K+28.0% | $289K |
| Inventory | $22.6M0.0% | $22.6M+31.6% | $17.2M+19.7% | $14.4M+73.9% | $8.3M | N/A | N/A | N/A |
| Accounts Receivable | $4.0M0.0% | $4.0M | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $51.6M0.0% | $51.6M-13.1% | $59.3M+20.6% | $49.2M+28.7% | $38.2M-23.4% | $49.9M-28.6% | $69.9M+3.0% | $67.8M |
| Current Liabilities | $44.7M0.0% | $44.7M-15.6% | $53.0M+22.1% | $43.4M+32.7% | $32.7M+1498.4% | $2.0M+341.0% | $464K+1357.1% | $32K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $58.4M0.0% | $58.4M+80.3% | $32.4M-21.5% | $41.3M-10.5% | $46.1M+103.0% | $22.7M+1154838.7% | -$2K-100.6% | $346K |
| Retained Earnings | $69.6M+200.0% | -$69.6M-17.8% | -$59.0M-28.5% | -$45.9M-17.0% | -$39.3M-1876.1% | -$2.0M-89842.5% | -$2K-100.6% | $345K |
CTOR Cash Flow Statement
| Metric | Q1'26 | Q1'25 | Q3'25 | Q1'24 | Q3'24 | Q3'23 | Q2'23 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $7.4M+200.0% | -$7.4M | N/A | N/A | -$366K-67.3% | -$219K-118.2% | -$100K | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $4.4M+200.0% | -$4.4M | N/A | N/A | $69K+110.4% | -$660K | N/A | N/A |
| Financing Cash Flow | $15.1M0.0% | $15.1M | N/A | N/A | $264K-70.1% | $885K | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CTOR Financial Ratios
| Metric | Q1'26 | Q1'25 | Q3'25 | Q1'24 | Q3'24 | Q3'23 | Q2'23 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.0%0.0pp | 80.0% | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | 133.2%+266.3pp | -133.2% | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | 140.3%+280.6pp | -140.3% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | 9.5% | N/A | N/A | N/A | N/A | 0.6%-309.0pp | 309.6% | N/A |
| Return on Assets | 5.0%+10.1pp | -5.0%+0.8pp | -5.9%+1.5pp | -7.4%+2.3pp | -9.7%-3.2pp | -6.5%-7.4pp | 0.9% | N/A |
| Current Ratio | 0.830.0 | 0.83+0.5 | 0.35-0.0 | 0.39+0.1 | 0.34+0.3 | 0.03-1.0 | 1.00-10.9 | 11.85 |
| Debt-to-Equity | 0.880.0 | 0.88-0.9 | 1.83+0.6 | 1.19+0.4 | 0.83-1.4 | 2.20+35496.3 | -35494.10-35690.5 | 196.36 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: The current ratio is below 1.0 (0.56), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
Is Citius Oncology, Inc. profitable?
No, Citius Oncology, Inc. (CTOR) reported a net income of -$24.8M in fiscal year 2025.
What is Citius Oncology, Inc.'s earnings per share (EPS)?
Citius Oncology, Inc. (CTOR) reported diluted earnings per share of $-0.34 for fiscal year 2025. This represents a -9.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Citius Oncology, Inc.'s operating cash flow?
Citius Oncology, Inc. (CTOR) generated -$5.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Citius Oncology, Inc.'s total assets?
Citius Oncology, Inc. (CTOR) had $100.9M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Citius Oncology, Inc. spend on research and development?
Citius Oncology, Inc. (CTOR) invested $6.4M in research and development during fiscal year 2025.
How many shares does Citius Oncology, Inc. have outstanding?
Citius Oncology, Inc. (CTOR) had 84M shares outstanding as of fiscal year 2025.
What is Citius Oncology, Inc.'s current ratio?
Citius Oncology, Inc. (CTOR) had a current ratio of 0.56 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Citius Oncology, Inc.'s debt-to-equity ratio?
Citius Oncology, Inc. (CTOR) had a debt-to-equity ratio of 1.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Citius Oncology, Inc.'s return on assets (ROA)?
Citius Oncology, Inc. (CTOR) had a return on assets of -24.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Citius Oncology, Inc.'s cash runway?
Based on fiscal year 2025 data, Citius Oncology, Inc. (CTOR) had $3.9M in cash against an annual operating cash burn of $5.5M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Citius Oncology, Inc.'s Piotroski F-Score?
Citius Oncology, Inc. (CTOR) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Citius Oncology, Inc.'s earnings high quality?
Citius Oncology, Inc. (CTOR) has an earnings quality ratio of 0.22x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Citius Oncology, Inc. cover its interest payments?
Citius Oncology, Inc. (CTOR) has an interest coverage ratio of -107.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.